MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies

Military Medical Research, Journal Year: 2025, Volume and Issue: 12(1)

Published: Jan. 27, 2025

Abstract Background Radiofrequency ablation (RFA) is an efficient treatment with unlimited potential for liver cancer that can effectively reduce patient mortality. Understanding the biological process related RFA important improving strategy. This study aimed to identify critical targets regulating efficacy of RFA. Methods The in hepatocellular carcinoma (HCC) tumor models vivo, was analyzed by RNA sequencing technology. heat vitro HCC cells also constructed explore mechanism after cells. Nanoparticles high affinity were applied as a new therapy interfere expression maternal embryonic leucine zipper kinase (MELK). Results It found upregulated MELK expression, and inhibition promoted immunogenic cell death antitumor response, including anti-tumoral macrophage polarization increased CD8 + T cytotoxicity HCC. Mechanically, binds fatty acid-binding protein 5 (FABP5), affects its ubiquitination through K48R pathway increase stability, thereby activating B (Akt)/mammalian target rapamycin (mTOR) signaling axis weaken RFA-mediated effect. In addition, synthesis arginylglycylaspartic acid (RGD)-lipid nanoparticles (LNPs) targeting cell-intrinsic enhanced Conclusion therapeutic HCC, via RGD-LNPs provides insight into clinical combating malignant progression cancer.

Language: Английский

---

Increased HBsAg loss in HBeAg-negative patients with chronic hepatitis B and concurrent MASLD

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Dyslipidemia and female reproductive failures: perspectives on lipid metabolism and endometrial immune dysregulation

Seminars in Immunopathology, Journal Year: 2025, Volume and Issue: 47(1)

Published: Feb. 18, 2025

Language: Английский

---

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

ABSTRACT Background and Aims Air pollution is associated with advanced liver fibrosis in patients chronic diseases, including hepatitis B (CHB). This study aimed to investigate the association between air mortality CHB treated nucleotide/nucleoside analogues. Methods We enrolled 697 analogues analysed incidence risk factors for mortality. Daily pollutant concentrations were estimated from year before enrolment. Results All‐cause showed an annual of 1.1/100 person‐years after a follow‐up period 3798.1 person‐years. Factors strongest all‐cause cirrhosis (hazard ratio [HR]/95% confidence interval [CI]: 3.95/1.69–9.23; p = 0.02), age ([HR]/CI: 1.07/1.03–1.17, < 0.001) pre‐treatment gamma‐glutamyl transferase (GGT) levels (HR/CI: 1.004/1.001–1.006, 0.004). Among cirrhosis, 1.08/1.04–1.12, 0.001), GGT 1.004/1.001–1.008, 0.01), platelet count 0.988/0.977–0.998, 0.02) NO x concentration (per unit increment, ppb) (1.045/1.001–1.091; 0.046). The best cut‐off value predicting was 25.5 ppb (AUROC 0.63; 0.03). > higher (HR/CI:2.49/1.03–6.02; 0.04). Conclusions influences receiving analogue therapy. Long‐term exposure may increase liver‐related treatment.

Language: Английский

---

Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword

Journal of Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 1, 2025

Language: Английский

---

Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider?

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: March 9, 2025

Introduction Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only small subset of patients. Current oral antiviral agents effectively suppress viral replication but fail to eliminate the virus (HBV). Recent advances immunomodulatory therapies offer new hope for improving rates.

Language: Английский

---

Retina and liver fibrosis screening for patients with type 2 diabetes

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2025, Volume and Issue: 10(5), P. 412 - 413

Published: April 9, 2025

Language: Английский

---